Suppr超能文献

吉森肺动脉高压注册研究:肺动脉高压亚组的生存情况。

The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.

机构信息

Pulmonary Hypertension Division, Medical Clinic II/V, University of Giessen, Marburg Lung Center, German Center for Lung Research, Giessen, Germany, and Department of Medicine, Imperial College London, UK; Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

J Heart Lung Transplant. 2017 Sep;36(9):957-967. doi: 10.1016/j.healun.2017.02.016. Epub 2017 Feb 17.

Abstract

BACKGROUND

Pulmonary hypertension (PH) is a severe, progressive disease. Although 5 PH subgroups are recognized, reports on survival have focused mainly on pulmonary arterial hypertension (PAH).

METHODS

Long-term transplant-free survival and its determinants were investigated in patients with PH (diagnosed by right heart catheterization) within a prospective registry at a single referral center in Giessen, Germany.

RESULTS

In total, 2,067 patients were enrolled (PAH, 685 patients [33.1%]; pulmonary venous hypertension, 307 patients [14.9%]; PH due to lung diseases (LD-PH), 546 patients [26.4%; mainly interstitial lung disease and chronic obstructive pulmonary disease]; chronic thromboembolic PH, 459 patients [22.2%]; PH owing to miscellaneous/unknown causes, 70 patients [3.4%]). Median follow-up was 37 months. Differences in transplant-free survival between etiologic groups were highly significant (p < 0.001), with 1-, 3- and 5-year survival rates of 88.2%, 72.2% and 59.4%, respectively, for those with PAH compared with 79.5%, 52.7% and 38.1%, respectively, for patients with LD-PH. Patients' age, gender and 6-minute walk distance (6MWD), but not New York Heart Association (NYHA) functional class, associated significantly with survival across all PH subtypes in multivariate Cox regression analyses.

CONCLUSIONS

This is the largest single-center PH cohort described so far. Some parameters used in clinical practice do not independently predict survival. Age, gender and 6MWD outperformed NYHA functional class in predicting survival across all etiologic groups.

摘要

背景

肺动脉高压(PH)是一种严重且进行性的疾病。虽然已经识别出 5 个 PH 亚组,但有关生存的报告主要集中在肺动脉高压(PAH)上。

方法

在德国吉森的一家单一转诊中心的前瞻性登记处,研究了 PH 患者(通过右心导管检查诊断)的长期无移植生存及其决定因素。

结果

共纳入 2067 例患者(PAH 患者 685 例[33.1%];肺静脉高压患者 307 例[14.9%];肺疾病(LD-PH)相关 PH 患者 546 例[26.4%;主要为间质性肺病和慢性阻塞性肺病];慢性血栓栓塞性 PH 患者 459 例[22.2%];PH 原因不明/未知患者 70 例[3.4%])。中位随访时间为 37 个月。不同病因组之间的无移植生存率差异具有高度显著性(p<0.001),PAH 患者的 1 年、3 年和 5 年生存率分别为 88.2%、72.2%和 59.4%,而 LD-PH 患者的相应生存率分别为 79.5%、52.7%和 38.1%。多变量 Cox 回归分析显示,患者年龄、性别和 6 分钟步行距离(6MWD),但不是纽约心脏协会(NYHA)功能分级,与所有 PH 亚组的生存显著相关。

结论

这是迄今为止描述的最大的单一中心 PH 队列。一些在临床实践中使用的参数并不能独立预测生存。年龄、性别和 6MWD 在预测所有病因组的生存方面优于 NYHA 功能分级。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验